REGULATORY
NIBIOHN Strengthens Collaboration with Drug Makers to Promote Development of Japan-Originated Drugs
The National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) will enhance its collaboration with pharma companies in order to promote the development of drugs of Japanese origin. Starting this fiscal year, Hirosato Kondo, who served as head of Shionogi’s…
To read the full story
Related Article
REGULATORY
- Japan Approves AbbVie’s Aquipta, Novo’s IcoSema, Pfizer’s Tukysa, and More
February 20, 2026
- Health Minister Signals Early March Approval for iPSC Products
February 20, 2026
- Takaichi Urges Public-Private Investment Push in Drug Discovery
February 20, 2026
- Two iPSC-Derived Products Now in Line for Conditional Approval
February 20, 2026
- PM Takaichi Keeps Cabinet Intact after Lower House Vote
February 18, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





